Pere Barba
Overview
Explore the profile of Pere Barba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
1924
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Iacoboni G, Sanchez-Salinas M, Rejeski K, Martin-Lopez A, Kwon M, Navarro V, et al.
Hemasphere
. 2024 Jul;
8(7):e86.
PMID: 38948924
Bridging therapy (BT) after leukapheresis is required in most relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T cells. Bendamustine-containing regimens are a potential BT option....
12.
Fox M, Garcia-Cadenas I, Navarro V, Perez Martinez A, Kara M, Bazan I, et al.
Bone Marrow Transplant
. 2024 Jun;
59(10):1369-1375.
PMID: 38914883
Despite novel cellular and immunomodulatory therapies, allogeneic hematopoietic stem cell transplantation (HSCT) remains a treatment option for lymphoid malignancies. Post-transplant cyclophosphamide (PTCY) is increasingly employed for graft vs. host disease...
13.
Iacoboni G, Iraola-Truchuelo J, OReilly M, Navarro V, Menne T, Kwon M, et al.
Hemasphere
. 2024 May;
8(5):e62.
PMID: 38774657
Over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line of therapy...
14.
Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, et al.
Blood
. 2024 Apr;
144(3):334-338.
PMID: 38657242
In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results...
15.
Leon-Roman J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, Garcia-Carro C, et al.
Clin Kidney J
. 2024 Mar;
17(3):sfae027.
PMID: 38500492
Background: Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes...
16.
Rudilla F, Carrasco-Benso M, Pasamar H, Lopez-Montanes M, Andres-Rozas M, Tomas-Marin M, et al.
HLA
. 2024 Mar;
103(3):e15419.
PMID: 38450972
Adoptive cell therapy using virus-specific T cells (VST) is a strategy for treating common opportunistic viral infections after transplantation, particularly when these infections do not resolve through antiviral drug therapy....
17.
Sanchez-Salinas M, Miarons M, Troconiz I, Navarro V, Varela J, Iacoboni G, et al.
Blood Adv
. 2024 Jan;
8(9):2130-2132.
PMID: 38231085
No abstract available.
18.
Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, et al.
Front Immunol
. 2024 Jan;
14:1303935.
PMID: 38187393
Lymphodepletion (LD) or conditioning is an essential step in the application of currently used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it maximizes engraftment, efficacy and long-term...
19.
Rejeski K, Wang Y, Hansen D, Iacoboni G, Bachy E, Bansal R, et al.
Blood Adv
. 2024 Jan;
8(8):1857-1868.
PMID: 38181508
Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can predispose for severe infectious complications. Current grading systems, such as the Common Terminology Criteria for Adverse...
20.
Ligero M, Simo M, Carpio C, Iacoboni G, Balaguer-Montero M, Navarro V, et al.
EJHaem
. 2023 Nov;
4(4):1081-1088.
PMID: 38024636
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment option for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). However, only a subset of patients will present long-term benefit....